Daniel Troy, a former chief counsel for the US Food and Drug Administration, will become senior vice president and general counsel for GlaxoSmithKline, effective 2 September 2008.
Mr Troy worked at the FDA from 2001 to 2004, during which period he acted as a primary liaison to the White House and to the Department of Health and Human Services. He joined the FDA shortly before the attacks of 11 September 2001 and helped it cope with the public health aftermath of the attacks. Thereafter, he provided legal support to the agency as it responded to a series of anthrax attacks. During his tenure, Mr Troy also oversaw many legislative activities including reforms to the Hatch-Waxman Act.
Mr Troy is currently a partner at the Washington law firm, Sidley Austin LLP, where he represents pharmaceutical companies and trade associations on matters related to the FDA.
Copyright 2008 Evernow Publishing Ltd